Premium
Precursor synthesis towards the development of [ 124 I]‐labelled 2′, 2′‐difluoro‐2′‐deoxycytidine as a potential pet radiotracer for the anticancer drug gemcitabine
Author(s) -
Wilson J.,
Hadfield J. A.,
Bailey J.,
Zweit J.,
Thatcher N.,
Little R.
Publication year - 2001
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.25804401343
Subject(s) - deoxycytidine , chemistry , gemcitabine , nucleoside analogue , deoxycytidine kinase , nucleoside , in vivo , pharmacokinetics , drug , cytidine , pharmacology , pet imaging , radiochemistry , combinatorial chemistry , stereochemistry , positron emission tomography , chemotherapy , nuclear medicine , biochemistry , medicine , microbiology and biotechnology , biology , enzyme
The anticancer nucleoside analogue, Gemcitabine (2′, 2′‐difluoro‐2′‐deoxycytidine) is an active nucleoside against solid tumours. Assessment of tumour and normal tissue concentration of drug in vivo provides pharmacokinetic data that can be related to response to treatment. Towards enabling PET imaging, the synthesis of a halogenated analogue has been undertaken for subsequent radiolabelling with 124 I.